About Abbott Laboratories (NYSE:ABT)
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:ABT
CUSIP00282410
Phone224-667-6100
Debt
Debt-to-Equity Ratio0.87%
Current Ratio2.26%
Quick Ratio1.86%
Price-To-Earnings
Trailing P/E Ratio23.95
Forward P/E Ratio20.94
P/E Growth1.76
Sales & Book Value
Annual Sales$27.39 billion
Price / Sales3.82
Cash Flow$4.8174 per share
Price / Cash12.43
Book Value$17.87 per share
Price / Book3.35
Profitability
EPS (Most Recent Fiscal Year)$2.50
Net Income$477 million
Net Margins1.67%
Return on Equity14.53%
Return on Assets6.29%
Miscellaneous
Employees99,000
Outstanding Shares1,746,330,000
Abbott Laboratories (NYSE:ABT) Frequently Asked Questions
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories declared a quarterly dividend on Friday, February 16th. Investors of record on Friday, April 13th will be paid a dividend of $0.28 per share on Tuesday, May 15th. This represents a $1.12 dividend on an annualized basis and a yield of 1.87%. The ex-dividend date is Thursday, April 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) announced its quarterly earnings data on Wednesday, April, 18th. The healthcare product maker reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.01. The healthcare product maker earned $7.39 billion during the quarter, compared to the consensus estimate of $7.28 billion. Abbott Laboratories had a net margin of 1.67% and a return on equity of 14.53%. The company's revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company posted $0.48 EPS. View Abbott Laboratories' Earnings History.
When is Abbott Laboratories' next earnings date?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories updated its FY18 earnings guidance on Wednesday, April, 18th. The company provided EPS guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.86. Abbott Laboratories also updated its Q2 guidance to $0.70-0.72 EPS.
What price target have analysts set for ABT?
18 equities research analysts have issued 1 year price targets for Abbott Laboratories' stock. Their predictions range from $45.00 to $80.00. On average, they expect Abbott Laboratories' share price to reach $67.00 in the next twelve months. View Analyst Ratings for Abbott Laboratories.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Novartis (NVS), Merck & Co. (MRK), AbbVie (ABBV), Novo Nordisk (NVO), Bayer (BAYRY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN) and Astellas Pharma (ALPMY).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Mr. Miles D. White, Chairman & CEO (Age 63)
- Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 48)
- Mr. Brian J. Blaser, Exec. VP of Diagnostic Products (Age 53)
- Scott M. Leinenweber, VP of Investor Relations
- Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 52)
Has Abbott Laboratories been receiving favorable news coverage?
Headlines about ABT stock have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abbott Laboratories earned a coverage optimism score of 0.22 on Accern's scale. They also assigned news articles about the healthcare product maker an impact score of 45.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Abbott Laboratories?
Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of ABT stock can currently be purchased for approximately $59.88.
How big of a company is Abbott Laboratories?
Abbott Laboratories has a market capitalization of $103.94 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.
How can I contact Abbott Laboratories?
Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.
MarketBeat Community Rating for Abbott Laboratories (ABT)
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Abbott Laboratories (NYSE:ABT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
18 Wall Street analysts have issued ratings and price targets for Abbott Laboratories in the last 12 months. Their average twelve-month price target is $67.00, suggesting that the stock has a possible upside of 11.89%. The high price target for ABT is $80.00 and the low price target for ABT is $45.00. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.78 | 2.74 | 2.76 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $67.00 | $65.5556 | $60.00 | $56.5333 |
| Price Target Upside: | 11.89% upside | 4.30% upside | 1.16% upside | 1.37% upside |
Abbott Laboratories (NYSE:ABT) Consensus Price Target History
Abbott Laboratories (NYSE:ABT) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Abbott Laboratories (NYSE:ABT) Dividend Information
Abbott Laboratories pays an annual dividend of $1.12 per share, with a dividend yield of 1.87%. ABT's next quarterly dividend payment will be made on Tuesday, May 15. The company has grown its dividend for the last 45 consecutive years and is increasing its dividend by an average of 6.40% each year. Abbott Laboratories pays out 44.80% of its earnings out as a dividend.
| Next Dividend: | 5/15/2018 |
| Annual Dividend: | $1.12 |
| Dividend Yield: | 1.87% |
| Dividend Growth: | 6.40% (3 Year Average) |
| Payout Ratio: | 44.80% (Trailing 12 Months of Earnings)
39.16% (Based on This Year's Estimates)
34.78% (Based on Next Year's Estimates)
|
| Track Record: | 45 Years of Consecutive Dividend Growth |
| Frequency: | Quarterly Dividend |
Abbott Laboratories (NYSE:ABT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 2/16/2018 | quarterly | $0.28 | 1.85415114642828% | 4/12/2018 | 4/13/2018 | 5/15/2018 |
| 12/15/2017 | quarterly | $0.28 | 1.99% | 1/11/2018 | 1/12/2018 | 2/15/2018 |
| 9/15/2017 | quarterly | $0.2650 | 2.05% | 10/12/2017 | 10/13/2017 | 11/15/2017 |
| 6/9/2017 | quarterly | $0.2650 | 2.25% | 7/12/2017 | 7/14/2017 | 8/15/2017 |
| 2/17/2017 | quarterly | $0.2650 | 2.36% | 4/11/2017 | 4/14/2017 | 5/15/2017 |
| 12/9/2016 | quarterly | $0.2650 | 2.7% | 1/11/2017 | 1/13/2017 | 2/15/2017 |
| 9/15/2016 | quarterly | $0.26 | 2.48% | 10/12/2016 | 10/14/2016 | 11/15/2016 |
| 6/10/2016 | quarterly | $0.26 | 2.75% | 7/13/2016 | 7/15/2016 | 8/15/2016 |
| 2/19/2016 | quarterly | $0.26 | 2.66% | 4/13/2016 | 4/15/2016 | 5/16/2016 |
| 12/11/2015 | quarterly | $0.26 | 2.32% | 1/13/2016 | 1/15/2016 | 2/16/2016 |
| 9/17/2015 | quarterly | $0.24 | 2.22% | 10/13/2015 | 10/15/2015 | 11/15/2015 |
| 6/12/2015 | quarterly | $0.24 | 2% | 7/13/2015 | 7/15/2015 | 8/15/2015 |
| 2/20/2015 | quarterly | $0.24 | 2.03% | 4/13/2015 | 4/15/2015 | 5/15/2015 |
| 12/12/2014 | quarterly | $0.24 | 2.21% | 1/13/2015 | 1/15/2015 | 2/13/2015 |
| 9/11/2014 | quarterly | $0.22 | 2.07% | 10/10/2014 | 10/15/2014 | 11/15/2014 |
| 6/13/2014 | quarterly | $0.22 | 2.21% | 7/11/2014 | 7/15/2014 | 8/15/2014 |
| 2/21/2014 | quarterly | $0.22 | 2.26% | 4/11/2014 | 4/15/2014 | 5/15/2014 |
| 10/16/2013 | quarterly | $0.22 | 2.37% | 1/13/2014 | 1/15/2014 | 2/15/2014 |
| 9/12/2013 | quarterly | $0.14 | 1.61% | 10/10/2013 | 10/15/2013 | 11/15/2013 |
| 6/14/2013 | quarterly | $0.14 | 1.52% | 7/11/2013 | 7/15/2013 | 8/15/2013 |
| 2/15/2013 | quarterly | $0.14 | 1.61% | 4/11/2013 | 4/15/2013 | 5/15/2013 |
| 12/14/2012 | quarterly | $0.14 | 0.86% | 1/11/2013 | 1/15/2013 | 2/15/2013 |
(Data available from 1/1/2013 forward)
Abbott Laboratories (NYSE ABT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.74%
Institutional Ownership Percentage: 72.34%
Abbott Laboratories (NYSE ABT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/9/2018 | Roger Bird | Insider | Sell | 8,262 | $62.75 | $518,440.50 | 58,574 |  |
| 3/7/2018 | Jared Watkin | Insider | Sell | 3,000 | $61.19 | $183,570.00 | 68,215 | |
| 3/5/2018 | Sharon J Bracken | SVP | Sell | 2,100 | $60.27 | $126,567.00 | 44,790 | |
| 3/1/2018 | Jared Watkin | SVP | Sell | 996 | $58.87 | $58,634.52 | 69,511 | |
| 3/1/2018 | Sharon J Bracken | Insider | Sell | 1,053 | $58.93 | $62,053.29 | | |
| 3/1/2018 | Stephen R Fussell | EVP | Sell | 11,106 | $60.13 | $667,803.78 | 172,158 | |
| 2/27/2018 | Daniel J Starks | Director | Buy | 40,037 | $60.67 | $2,429,044.79 | 6,943,348 | |
| 2/20/2018 | Jared Watkin | SVP | Sell | 297 | $59.29 | $17,609.13 | 74,357 | |
| 2/20/2018 | Stephen R Fussell | Insider | Sell | 56,401 | $59.61 | $3,362,063.61 | 184,884 | |
| 1/31/2018 | Brian J Blaser | Insider | Sell | 27,733 | $62.26 | $1,726,656.58 | 156,587 | |
| 1/30/2018 | Stephen R Fussell | EVP | Sell | 13,313 | $62.84 | $836,588.92 | 152,343 | |
| 12/14/2017 | Daniel Gesua Sive Salvadori | Insider | Sell | 28,319 | $54.92 | $1,555,279.48 | 102,117 | |
| 12/6/2017 | Miles D White | Chairman | Sell | 276,886 | $54.41 | $15,065,367.26 | 3,677,913 | |
| 11/30/2017 | Sharon J Bracken | Insider | Sell | 2,188 | $56.12 | $122,790.56 | 25,618 | |
| 11/22/2017 | Alejandro D Wellisch | Insider | Sell | 2,153 | $55.86 | $120,266.58 | 10,256 | |
| 11/17/2017 | Brian J Blaser | Insider | Sell | 23,866 | $55.55 | $1,325,756.30 | 146,387 | |
| 11/14/2017 | Daniel Gesua Sive Salvadori | Insider | Sell | 71,157 | $55.00 | $3,913,635.00 | 144,955 | |
| 10/23/2017 | Daniel Gesua Sive Salvadori | EVP | Sell | 96,603 | $56.21 | $5,430,054.63 | 142,082 | |
| 9/26/2017 | Daniel Gesua Sive Salvadori | Insider | Sell | 62,460 | $52.95 | $3,307,257.00 | 113,426 | |
| 9/22/2017 | Jaime Contreras | Insider | Sell | 52,700 | $51.97 | $2,738,819.00 | 58,739 | |
| 8/16/2017 | Stephen R Fussell | Insider | Sell | 196,550 | $49.50 | $9,729,225.00 | 221,488 | |
| 8/1/2017 | Sharon J Bracken | Insider | Sell | 2,000 | $49.16 | $98,320.00 | 28,806 | |
| 7/27/2017 | Brian J Blaser | Insider | Sell | 15,000 | $50.00 | $750,000.00 | 143,154 | |
| 7/25/2017 | Hubert L Allen | Insider | Sell | 4,600 | $50.79 | $233,634.00 | 105,479 | |
| 6/15/2017 | Jared Watkin | Insider | Sell | 552 | $47.97 | $26,479.44 | 47,090 | |
| 6/8/2017 | Stephen R Fussell | Insider | Sell | 196,550 | $46.00 | $9,041,300.00 | 221,488 | |
| 4/27/2017 | Roger Bird | Insider | Sell | 5,600 | $43.82 | $245,392.00 | 51,313 | |
| 4/26/2017 | Joseph J Manning | Insider | Sell | 4,200 | $43.95 | $184,590.00 | 26,224 | |
| 3/1/2017 | Michael J. Warmuth | Insider | Sell | 3,851 | $45.39 | $174,796.89 | | |
| 2/23/2017 | Robert E Funck | VP | Sell | 25,500 | $45.50 | $1,160,250.00 | 117,579 | |
| 2/22/2017 | Roger Bird | Insider | Sell | 13,222 | $45.02 | $595,254.44 | 63,910 | |
| 2/21/2017 | Deepak S Nath | Insider | Sell | 319 | $44.98 | $14,348.62 | 58,471 | |
| 1/31/2017 | Heather L Mason | Insider | Sell | 35,700 | $40.77 | $1,455,489.00 | 100,189 | |
| 12/20/2016 | Brian J Blaser | Insider | Buy | 15,580 | $38.45 | $599,051.00 | 129,782 | |
| 12/14/2016 | Robert B Ford | Insider | Buy | 12,775 | $39.09 | $499,374.75 | 51,532 | |
| 11/10/2016 | Miles D White | Chairman | Buy | 121,456 | $40.45 | $4,912,895.20 | 2,802,558 | |
| 11/1/2016 | Sally E Blount | Director | Buy | 5,100 | $39.24 | $200,124.00 | 20,143 | |
| 9/26/2016 | Daniel Gesua Sive Salvadori | SVP | Sell | 815 | $41.71 | $33,993.65 | 59,791 | |
| 7/28/2016 | Stephen R Fussell | Insider | Sell | 41,500 | $45.00 | $1,867,500.00 | 196,467 | |
| 7/26/2016 | Michael J Warmuth | Insider | Sell | 26,800 | $43.49 | $1,165,532.00 | 81,811 | |
| 7/25/2016 | Miles D White | Chairman | Buy | 242,547 | $43.18 | $10,473,179.46 | 2,010,517 | |
| 7/25/2016 | Robert E Funck | VP | Sell | 26,800 | $43.08 | $1,154,544.00 | 111,819 | |
| 6/28/2016 | Hubert L Allen | EVP | Sell | 3,400 | $37.14 | $126,276.00 | 91,857 | |
| 6/15/2016 | Jared Watkin | SVP | Sell | 552 | $37.63 | $20,771.76 | 47,114 | |
| 6/1/2016 | Brian B Yoor | CFO | Sell | 565 | $39.49 | $22,311.85 | 50,182 | |
| 4/28/2016 | Deepak S Nath | SVP | Sell | 53 | $41.31 | $2,189.43 | 47,435 | |
| 3/31/2016 | Jaime Contreras | SVP | Sell | 462 | $41.78 | $19,302.36 | 47,667 | |
| 2/29/2016 | Brian B Yoor | CFO | Sell | 865 | $39.12 | $33,838.80 | 52,250 | |
| 2/29/2016 | Deepak S Nath | SVP | Sell | 793 | $39.27 | $31,141.11 | 48,364 | |
| 2/29/2016 | Robert B Ford | EVP | Sell | 1,706 | $39.28 | $67,011.68 | 62,495 | |
| 2/29/2016 | Robert E Funck | VP | Sell | 1,333 | $39.30 | $52,386.90 | 86,352 | |
| 2/22/2016 | Jared Watkin | SVP | Sell | 554 | $39.09 | $21,655.86 | 50,515 | |
| 2/16/2016 | Deepak S. Nath | SVP | Sell | 171 | $37.13 | $6,349.23 | 34,941 | |
| 12/16/2015 | Miles D. White | CEO | Sell | 438,000 | $46.00 | $20,148,000.00 | 1,394,153 | |
| 8/18/2015 | Stephen R. Fussell | EVP | Sell | 13,096 | $50.46 | $660,824.16 | 130,601 | |
| 4/27/2015 | Heather L Mason | EVP | Sell | 13,500 | $47.45 | $640,575.00 | | |
| 4/27/2015 | Roger Bird | SVP | Sell | 28,548 | $47.57 | $1,358,028.36 | | |
| 3/26/2015 | J. Scott White | SVP | Sell | 12,483 | $46.68 | $582,706.44 | | |
| 3/2/2015 | Jaime Contreras | SVP | Sell | 9,209 | $47.34 | $435,954.06 | | |
| 2/4/2015 | John M Capek | EVP | Sell | 34,292 | $45.66 | $1,565,772.72 | | |
| 11/25/2014 | Jaime Contreras | SVP | Sell | 51,600 | $44.07 | $2,274,012.00 | | |
| 10/29/2014 | Miles D White | CEO | Sell | 440,800 | $42.52 | $18,742,816.00 | | |
| 3/3/2014 | John Landgraf | EVP | Sell | 17,293 | $39.38 | $680,998.34 | 95,131 | |
| 3/3/2014 | Katherine Doyle | SVP | Sell | 6,639 | $39.01 | $258,987.39 | 47,525 | |
| 3/3/2014 | Robert Funck | VP | Sell | 1,413 | $38.97 | $55,064.61 | 62,926 | |
| 2/18/2014 | John Landgraf | EVP | Sell | 1,583 | $39.10 | $61,895.30 | 102,421 | |
| 1/29/2014 | Michael Warmuth | EVP | Sell | 11,430 | $36.21 | $413,880.30 | 40,487 | |
| 12/6/2013 | Jean-Yves Pavee | SVP | Sell | 5,855 | $37.46 | $219,328.30 | 30,901 | |
| 11/7/2013 | Stephen Fussell | EVP | Sell | 10,466 | $37.59 | $393,416.94 | 101,169 | |
| 10/30/2013 | Jaime Contreras | SVP | Sell | 25,368 | $36.85 | $934,810.80 | | |
| 6/7/2013 | Heather L Mason | SVP | Sell | 12,000 | $37.01 | $444,120.00 | | |
| 2/1/2013 | William A Osborn | Director | Buy | 10,000 | $33.86 | $338,600.00 | | |
(Data available from 1/1/2013 forward)
Abbott Laboratories (NYSE ABT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Earnings Reaction History: Abbott Laboratories, 63.6% Follow-Through Indicator, 2.4% Sensitive
www.nasdaq.com - April 20 at 8:33 AM |
 | FY2018 EPS Estimates for Abbott Laboratories Increased by William Blair (ABT)
www.americanbankingnews.com - April 20 at 8:32 AM |
| Abbott Laboratories (ABT) to Post Q3 2018 Earnings of $0.73 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - April 20 at 8:08 AM |
| Jefferies Group Weighs in on Abbott Laboratories' Q3 2018 Earnings (ABT)
www.americanbankingnews.com - April 20 at 8:08 AM |
| Abbott Laboratories (ABT) Earns Hold Rating from BMO Capital Markets
www.americanbankingnews.com - April 19 at 5:50 PM |
 | Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves
finance.yahoo.com - April 19 at 5:32 PM |
 | Abbott Laboratories (ABT) Q1 2018 Earnings Conference Call Transcript
www.msn.com - April 19 at 8:52 AM |
 | Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained
www.zacks.com - April 18 at 5:12 PM |
 | Abbott Laboratories' (ABT) CEO Miles White on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 18 at 5:12 PM |
 | Abbott CEO: New Glucose Device's U.S. Launch 'Has Gone Exceptionally Well'
www.thestreet.com - April 18 at 5:12 PM |
| Is Abbott Laboratories’s (NYSE:ABT) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - April 18 at 5:12 PM |
| Abbott Shares Topple After Pharma Unit Struggles In First Quarter
finance.yahoo.com - April 18 at 5:12 PM |
 | Abbott Laboratories Stock Slips Despite Earnings Beat
investorplace.com - April 18 at 1:13 PM |
 | Earnings In Focus: Apr. 18 (ABT, PIR, STLD)
www.finanznachrichten.de - April 18 at 8:53 AM |
| Abbott Laboratories Q1 adjusted earnings Beat Estimates
www.nasdaq.com - April 18 at 8:53 AM |
 | Abbott Labs' quarterly revenue rises 16.7 percent
www.reuters.com - April 18 at 8:53 AM |
| Abbott (ABT) Beats on Earnings and Revenues in Q1
www.zacks.com - April 18 at 8:53 AM |
| Abbott: 1Q Earnings Snapshot
finance.yahoo.com - April 18 at 8:53 AM |
| Abbott Reports First-Quarter 2018 Results
finance.yahoo.com - April 18 at 8:53 AM |
| Abbott's quarterly profit, sales beat Street estimates
finance.yahoo.com - April 18 at 8:53 AM |
| Abbott Laboratories Tops Q1 Earnings Estimates, Issues Full Year Guidance
finance.yahoo.com - April 18 at 8:53 AM |
| Abbott Labs beats profit and sales expectations, shares slip
finance.yahoo.com - April 18 at 8:53 AM |
| Abbott Laboratories Earnings Top Views On Solid Organic Sales
finance.yahoo.com - April 18 at 8:53 AM |
| Abbott Laboratories (ABT) Issues Q2 Earnings Guidance
www.americanbankingnews.com - April 18 at 8:50 AM |
| Abbott Laboratories (ABT) Issues FY18 Earnings Guidance
www.americanbankingnews.com - April 18 at 8:50 AM |
| Abbott Laboratories (ABT) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - April 18 at 8:50 AM |
| Analysts Anticipate Abbott Laboratories (ABT) Will Post Quarterly Sales of $7.26 Billion
www.americanbankingnews.com - April 18 at 3:02 AM |
| Abbott's New Ensure® Max Protein Helps Americans Go for Their #HealthGoals
finance.yahoo.com - April 17 at 5:23 PM |
| Glucose Monitoring Device in Focus as Abbott Preps to Unveil Earnings
finance.yahoo.com - April 17 at 5:23 PM |
| 3 Stocks to Buy Ahead of Earnings
finance.yahoo.com - April 16 at 5:22 PM |
| Is Abbott Laboratories (NYSE:ABT) Worth $58.49 Based On Intrinsic Value?
finance.yahoo.com - April 16 at 5:22 PM |
| Zacks: Analysts Expect Abbott Laboratories (ABT) to Announce $0.58 Earnings Per Share
www.americanbankingnews.com - April 16 at 1:08 PM |
| BidaskClub Lowers Abbott Laboratories (ABT) to Buy
www.americanbankingnews.com - April 15 at 12:36 AM |
| Abbott Laboratories (ABT) Given "Buy" Rating at Jefferies Group
www.americanbankingnews.com - April 13 at 11:43 PM |
| Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?
finance.yahoo.com - April 13 at 5:19 PM |
| Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?
finance.yahoo.com - April 13 at 5:19 PM |
| Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?
www.zacks.com - April 12 at 9:04 AM |
| Abbott Initiates Groundbreaking Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery Disease
finance.yahoo.com - April 11 at 5:13 PM |
| Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?
finance.yahoo.com - April 11 at 5:13 PM |
| Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?
www.zacks.com - April 11 at 8:50 AM |
| Abbott Laboratories (ABT) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 11 at 1:34 AM |
| Abbott Laboratories Stock Performance in 1Q18
finance.yahoo.com - April 10 at 5:17 PM |
| New Trial Data Show Improved Clinical Outcomes with HeartMate3
finance.yahoo.com - April 9 at 5:18 PM |
 | Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Abbott Laboratories, ABIOMED, Align Technology, and Avinger
www.bizjournals.com - April 9 at 9:04 AM |
| Abbott Laboratories' (ABT) Buy Rating Reiterated at Royal Bank of Canada
www.americanbankingnews.com - April 8 at 11:01 AM |
| Abbott Laboratories (ABT) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 7 at 9:11 AM |
| Abbott Laboratories (ABT) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 5 at 10:15 AM |
| Abbott Laboratories (ABT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 4 at 12:34 AM |
| Abbott Starts GUIDE-HF Clinical Trial for CardioMEMS Device
finance.yahoo.com - April 2 at 5:27 PM |
| Zacks: Analysts Expect Abbott Laboratories (ABT) Will Announce Quarterly Sales of $7.26 Billion
www.americanbankingnews.com - April 1 at 2:50 AM |
Abbott Laboratories (NYSE:ABT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Abbott Laboratories (NYSE:ABT) Income Statement, Balance Sheet and Cash Flow Statement
Abbott Laboratories (NYSE ABT) Stock Chart for Friday, April, 20, 2018
Loading chart…
